Evommune, Inc.
EVMN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002044725
No open-market purchases or sales by Evommune, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $462.5M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $315.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +24 vs. previous quarter
- 105
- 13F valueReported value at the end of Q2 2026
- $462.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $13.0M
- No comparable prior period
- Net income, FY2025
- -$68.9M
- No comparable prior period
- Free cash flow, FY2025
- -$76.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $68.9M (529.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.39M
- Shares sold short
- Change
- −146.4K
- −4.1% vs. previous
- Days to cover
- 2.96
- At average daily volume
Superinvestors holding EVMN, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding EVMN at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Evommune, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)7:59 PM ET | Jul 8 | 2 days | Carver KyleChief Financial Officer | PPurchase | +1.00K | $13.26 | +$13.3K | +1.7%60.3K after | |
| Jul 8, 2026 (view filing)8:00 PM ET | Jul 7 | 1 day | Kirsch Arthur SDirector | PPurchase | +10.0K | $13.30 | +$133.0K | New position10.0K after | |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Patel Jeegar PravinkumarChief Scientific Officer | SSale | −1.49K | $22.50 | −$33.5K | −3.1%46.4K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Drew Janice SuzannChief of Dev. Operations | SSale | −20.0K | $22.63 | −$452.6K | −22.8%67.8K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Pena Luis C.President & CEO | SSale | −7.44K | $22.71 | −$168.9K | −1.2%630.5K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Patel Jeegar PravinkumarChief Scientific Officer | SSale | −16.7K | $22.74 | −$379.5K | −26.4%46.4K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Pena Luis C.President & CEO | SSale | −16.8K | $22.74 | −$381.7K | −2.6%637.9K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Cohen David EDirector | SSale | −6.06K | $20.33 | −$123.1K | −25.6%17.6K after | 2 lots10b5-1 |
| Jun 1, 2026 (view filing) | May 28 | 4 days | Carver KyleChief Financial Officer | SSale | −18.2K | $22.84 | −$415.1K | −23.4%59.3K after | 10b5-1 |
| Jun 1, 2026 (view filing) | May 28 | 4 days | Moss Gregory S.Chief Business & Legal Officer | SSale | −14.2K | $22.83 | −$324.7K | −18.9%60.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 105 holdersThe largest institutional positions in Evommune, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,288,313 | $70.3M | 8.15% | +358,680+7.3% | Added |
| Ra Capital Management, L.P. | 3,494,638 | $46.4M | 0.40% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 1,940,939 | $25.8M | 0.00% | +821,918+73.4% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,926,943 | $25.6M | 8.32% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 1,553,132 | $23.4M | 0.00% | +93,712+6.4% | Added |
| RTW Investments, LP | 1,502,235 | $20.0M | 0.17% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 1,441,032 | $19.2M | 14.56% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 1,435,049 | $19.1M | 0.03% | +1,398,472+3,823.4% | Added |
| Andera Partners | 1,391,990 | $18.5M | 8.96% | −505,372−26.6% | Reduced |
| Eventide Asset Management, LLC | 1,209,129 | $16.1M | 0.21% | 00.0% | Unchanged |
Holders of 5% or more of EVMN
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Evommune, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| LSP 7 Cooperative UA | 13D/A | 14.70%5.29M shares | −1.00 ppfrom 15.70% | Nov 14, 20252 filings | Feb 19, 2026 | SEC |
| Pivotal bioVenture Partners Fund I, L.P. | 13G | 10.90%3.44M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Ra Capital Management, L.P. | 13D/A | 8.50%3.49M shares | −1.20 ppfrom 9.70% | Nov 17, 20253 filings | Nov 10, 2026 | SEC |
| Price T Rowe Associates Inc | 13G | 5.40%1.94M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Point72 Asset Management, L.P. | 13G | 5.30%1.91M shares | New | Jul 16, 20261 filing | Jul 16, 2026 | SEC |